Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion

NCT00150085 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients

Interventions

DRUG: cyclosporine micro-emulsion

Sponsor

Novartis